Wednesday, October 30, 2013

Immune Design Gets $49M For Cancer Therapy

San Francisco- and Seattle-based Immune Design said this morning that it has raised $49M in a funding round, to go towards its immune-based therapies for cancer and other conditions. The Series C funding came from The Column Group, and also included Topspin Partners, Alta Partners, Versant Ventures, Osage Partners, ProQuest Investments, as well as Sanofi-Genzyme BioVentures. According to Immune Design, the funding is split into two tranches, including $32.5M upfront and $16.5M in the near future based on program progress. More information »